UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy

Journal of clinical oncology, 2016-11, Vol.34 (32), p.3914-3920

2016

Volltextzugriff (PDF)

Biology of Prostate-Specific Antigen

Journal of clinical oncology, 2003-01, Vol.21 (2), p.383-391

2003

Volltextzugriff (PDF)

Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group

Journal of clinical oncology, 2004-06, Vol.22 (11), p.2122-2132

2004

Volltextzugriff (PDF)

The impact of African ancestry on colorectal cancer disparity

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3621-3621

2022

Volltextzugriff (PDF)

A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.247-247

2019

Volltextzugriff (PDF)

A single-arm, phase II study of intrahepatic chemotherapy in patients with unresectable colorectal liver metastases

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.162-162

2020

Volltextzugriff (PDF)

Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Journal of clinical oncology, 2023-04, Vol.41 (11), p.2007-2019

2023

Volltextzugriff (PDF)

Efficacy and safety of regorafenib compared to TAS-102 for refractory metastatic colorectal cancer

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e15010-e15010

2016

Volltextzugriff (PDF)

Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4073-4073

2023

Volltextzugriff (PDF)

A systematic review of post first-line treatments for advanced gastrointestinal stromal tumor (GIST): Direct pairwise meta-analyses and indirect comparisons

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.195-195

2015

Volltextzugriff (PDF)

FDG PET/CT in pancreatic cancer staging and management: A retrospective study

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.464-464

2017

Volltextzugriff (PDF)

Efficacy and safety of regorafenib compared to TAS-102 for metastatic colorectal cancer: A systematic review and network meta-analysis

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.735-735

2017

Volltextzugriff (PDF)

GATA6 Expression as a predictor of response to perioperative chemotherapy in resectable pancreatic adenocarcinoma: A multicenter Canadian phase II study (NeoPancONE)

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS638-TPS638

2022

Volltextzugriff (PDF)

A network meta-analysis of adjuvant systemic therapy in resected pancreatic cancer

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.396-396

2019

Volltextzugriff (PDF)

Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A multicenter analysis from the CHORD consortium

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.650-650

2020

Volltextzugriff (PDF)

Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4135-4135

2021

Volltextzugriff (PDF)

Oncology education for internal medicine residents: The value of participating in a medical oncology rotation

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e18175-e18175

2016

Volltextzugriff (PDF)

Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.411-411

2021

Volltextzugriff (PDF)

Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A Canadian multicenter analysis from the CHORD Consortium

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e15717-e15717

2019

Volltextzugriff (PDF)

Treatment of hepatocellular carcinoma (HCC) after sorafenib (S) over the last 10 years

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.438-438

2019

Volltextzugriff (PDF)

Prognostic factors associated with long term survival in chemotherapy-treated advanced pancreatic cancer: A Canadian multicenter analysis

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.416-416

2019

Volltextzugriff (PDF)

Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S)

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.422-422

2019

Volltextzugriff (PDF)

Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4618-4618

2020

Volltextzugriff (PDF)

A network meta-analysis-based cost-effectiveness analysis of systematic therapies in advanced pancreatic cancer

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.6611-6611

2015

Volltextzugriff (PDF)

Do clinical trial acronyms affect patients’ interest in clinical trials? A randomized survey

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.6639-6639

2013

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(50)

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy

Biology of Prostate-Specific Antigen

Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group

The impact of African ancestry on colorectal cancer disparity

A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers

A single-arm, phase II study of intrahepatic chemotherapy in patients with unresectable colorectal liver metastases

Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Efficacy and safety of regorafenib compared to TAS-102 for refractory metastatic colorectal cancer

Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)

A systematic review of post first-line treatments for advanced gastrointestinal stromal tumor (GIST): Direct pairwise meta-analyses and indirect comparisons

FDG PET/CT in pancreatic cancer staging and management: A retrospective study

Efficacy and safety of regorafenib compared to TAS-102 for metastatic colorectal cancer: A systematic review and network meta-analysis

GATA6 Expression as a predictor of response to perioperative chemotherapy in resectable pancreatic adenocarcinoma: A multicenter Canadian phase II study (NeoPancONE)

A network meta-analysis of adjuvant systemic therapy in resected pancreatic cancer

Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A multicenter analysis from the CHORD consortium

Predictive value of germline ATM mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

Oncology education for internal medicine residents: The value of participating in a medical oncology rotation

Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A Canadian multicenter analysis from the CHORD Consortium

Treatment of hepatocellular carcinoma (HCC) after sorafenib (S) over the last 10 years

Prognostic factors associated with long term survival in chemotherapy-treated advanced pancreatic cancer: A Canadian multicenter analysis

Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S)

Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial

A network meta-analysis-based cost-effectiveness analysis of systematic therapies in advanced pancreatic cancer

Do clinical trial acronyms affect patients’ interest in clinical trials? A randomized survey

Aktive Filter

Suchergebnisse filtern